Small Cell Carcinoma of the Lung
作者： Emer O. Hanrahan , Bonnie Glisson
DOI: 10.1007/978-1-60761-524-8_16
关键词: Lung cancer 、 Internal medicine 、 Prophylactic cranial irradiation 、 Extensive stage 、 Small-cell carcinoma 、 Oncology 、 Lung 、 Etoposide 、 Limited Stage 、 Topotecan 、 Medicine
摘要: Small cell lung cancer (SCLC) is a malignant epithelial tumor that occurs almost exclusively in smokers. It accounts for approximately 13% of diagnoses the United States annually. For treatment planning, SCLC divided into either limited stage disease (LS-SCLC- is, confined to chest and can be encompassed within tolerable radiation field)- or extensive (ES-SCLC). Approximately 60-70% patients with have (ES-SCLC) at diagnosis. With treatment, median survival times are about 18-30 months LS-SCLC 8-12 ES-SCLC.
springer.com
sci-hub.st 参考文章(201)
D. R. Spigel, J. D. Hainsworth, C. Farley, C. Meng, D. Blake, H. A. Burris, E. Raefsky, J. Patton, L. L. Hart, F. A. Greco, Tracheoesophageal (TE) fistula development in a phase II trial of concurrent chemoradiation (CRT) and bevacizumab (B) in limited-stage small-cell lung cancer (LS-SCLC) Journal of Clinical Oncology. ,vol. 26, pp. 7554- 7554 ,(2008) , 10.1200/JCO.2008.26.15_SUPPL.7554
H S Brodovsky, J H Edmonson, G Wampler, M Levitt, J M Bennett, F M Muggia, R Creech, L Israel, S W Lagakos, J Colsky, E M Greenspan, E Z Ezdinli, J Horton, P P Carbone, E G Mansour, O S Selawry, C P Perlia, L Stolbach, Cyclophosphamide and CCNU in the treatment of inoperable small cell carcinoma and adenocarcinoma of the lung. Cancer treatment reports. ,vol. 60, pp. 925- 932 ,(1976)
S. I. Jalal, S. Bhatia, L. H. Einhorn, R. H. Ansari, N. Bechar, R. Govindan, K. Koneru, P. M. Bedano, J. Wu, N. H. Hanna, Paclitaxel (P) plus bevacizumab (B) in patients (pts) with chemosensitive relapsed small cell lung cancer (SCLC): A safety, feasibility and efficacy trial from the Hoosier Oncology Group Journal of Clinical Oncology. ,vol. 26, pp. 19013- 19013 ,(2008) , 10.1200/JCO.2008.26.15_SUPPL.19013
Pasi A. Jänne, Boris Freidlin, Scott Saxman, David H. Johnson, Robert B. Livingston, Frances A. Shepherd, Bruce E. Johnson, Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America: Meaningful improvements in survival Cancer. ,vol. 95, pp. 1528- 1538 ,(2002) , 10.1002/CNCR.10841
J-L Pujol, Carestia, J-P Daurès, Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent British Journal of Cancer. ,vol. 83, pp. 8- 15 ,(2000) , 10.1054/BJOC.2000.1164
Reinhard Dammann, Chun Li, Jung-Hoon Yoon, Philip L. Chin, Steven Bates, Gerd P. Pfeifer, Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nature Genetics. ,vol. 25, pp. 315- 319 ,(2000) , 10.1038/77083
LH Sobin, WD Travis, TV Colby, B Corrin, Y Shimosato, E Brambilla, Histological Typing of Lung and Pleural Tumours ,(1999)
Lee M. Krug, John P. Crapanzano, Christopher G. Azzoli, Vincent A. Miller, Naiyer Rizvi, Jorge Gomez, Mark G. Kris, Barbara Pizzo, Leslie Tyson, Megan Dunne, Robert T. Heelan, Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial. Cancer. ,vol. 103, pp. 2128- 2131 ,(2005) , 10.1002/CNCR.21000
Yan Xu, Hongyu Liu, Jun Chen, Qinghua Zhou, Comparisons between the National Comprehensive Cancer Network (NCCN) non‐small‐cell lung cancer (NSCLC) Clinical Practice Guidelines (Chinese version), the NCCN original edition, and the European Society for Medical Oncology NSCLC Guidelines in 2009 Thoracic Cancer. ,vol. 1, pp. 83- 86 ,(2010) , 10.1111/J.1759-7714.2010.00016.X
S Gazzeri, E Brambilla, C Brambilla, L Chaussade, C J Larsen, V Della Valle, The human p19ARF protein encoded by the beta transcript of the p16INK4a gene is frequently lost in small cell lung cancer. Cancer Research. ,vol. 58, pp. 3926- 3931 ,(1998)